Caduceus Biotechnology Inc. Invited to Attend 2025 CPCC Forum on Clinical Proteomic Microarray Applications

Chairman Rung-Ywan Tsai (sixth from the right)

Chairman Tsai of Caduceus Biotechnology Inc. was invited to attend the 2025 CPCC Forum on Clinical Proteomic Microarray Applications, hosted by the Consortium for High-Throughput Protein Microarray Technology and Biomedical Industry Services (CPCC). The forum was held on December 12, 2025, at the Biomedical Innovation Building, Cheng Kung University (Cheng-Hsing Campus), bringing together experts from industry, academia, research institutes, and clinical practice to discuss the latest applications and future directions of clinical proteomic microarray technologies in precision medicine.

The forum focused on recent breakthroughs in high-throughput protein microarray technologies and their translation into clinical and industrial applications. Key topics included antibody–drug conjugate (ADC) development, cancer immunotherapy and therapeutic target design, neurodegenerative diseases (with a focus on gut–brain axis mechanisms), as well as diagnostic applications for autoimmune and rare diseases. The program highlighted both cutting-edge research and practical clinical insights.

During the forum, Chairman Tsai engaged in in-depth discussions with fellow experts and shared Caduceus Biotechnology Inc.’s practical experience in proteomic assay development, clinical biomarker discovery, and digitalized analytical platforms. Chairman Tsai emphasized that as the demand for precision medicine continues to grow, high-sensitivity, high-throughput, and clinically actionable proteomic platforms will play a critical role in early disease screening, risk stratification, and therapeutic response monitoring.

Through the academic exchange and technical sharing at this forum, participants witnessed how high-throughput proteomic platforms can significantly accelerate biomarker discovery and drug evaluation, facilitating the translation of research outcomes into clinical and industrial applications. Caduceus Biotechnology Inc. will continue to strengthen collaborations with academic, research, and medical institutions to advance the clinical implementation of proteomic technologies and contribute to the sustainable development of precision medicine.